Surgical resection of residual tumor masses after chemotherapy in testicular cancer

2012 ◽  
Vol 84 (2) ◽  
pp. 84-91
Author(s):  
D. P. Korkolis ◽  
Ch. Aggeli ◽  
I. Passas ◽  
E. Gontikakis
Keyword(s):  
Testicular Cancer ◽  
Surgical Resection ◽  
Residual Tumor

Surgical resection of residual tumor after chemotherapy in non-seminomatous testicular cancer

1982 ◽  
Vol 18 (12) ◽  
pp. 1259-1265 ◽  
Author(s):  
R.A. Stahel ◽  
A.R. von Hochstetter ◽  
F. Largiadér ◽  
O. Schmucki ◽  
H.P. Honegger
Keyword(s):  
Testicular Cancer ◽  
Surgical Resection ◽  
Residual Tumor

1001: Retroperitoneal Residual Tumor (RTR) Resection for Testicular Cancer - Template Instead of Full Bilateral Resection

2007 ◽  
Vol 177 (4S) ◽  
pp. 331-331 ◽  
Author(s):  
Ralf Witthuhn ◽  
Patrick De Geeter ◽  
Peter Albers
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

Management of Residual Tumor in Testicular Cancer

2019 ◽  
pp. 701-705
Author(s):  
David Pfister ◽  
Axel Heidenreich
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

Management of Residual Tumor in Testicular Cancer

2018 ◽  
pp. 1-5
Author(s):  
D. Pfister ◽  
A. Heidenreich
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer

Cancer ◽  
1985 ◽  
Vol 56 (2) ◽  
pp. 249-255 ◽  
Author(s):  
Giorgio Pizzocaro ◽  
Roberto Salvioni ◽  
Massimo Pasi ◽  
Fulvio Zanoni ◽  
Angelo Milani ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Combination Chemotherapy ◽  
Residual Tumor ◽  
Stage Ii ◽  
Stage Iii

Combined Surgical Resection and Laser Interstitial Thermal Therapy for Glioblastoma: Technical Note

2020 ◽  
Vol 81 (04) ◽  
pp. 348-354
Author(s):  
Rafael A. Vega ◽  
Jeffrey I. Traylor ◽  
Rajan Patel ◽  
Matthew Muir ◽  
Dheigo C.A. Bastos ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Malignant Gliomas ◽  
Length Of Hospital Stay ◽  
Residual Tumor ◽  
Technical Note ◽  
Thermal Therapy ◽  
Cancer Center ◽  
Invasive Technique ◽  
Laser Interstitial Thermal Therapy

Abstract Background Glioblastoma multiforme (GBM) is an aggressive intracranial malignancy that confers a poor prognosis despite maximum surgical resection and chemoradiotherapy. Survival decreases further with deep-seated lesions. Laser interstitial thermal therapy (LITT) is an emerging minimally invasive technique for tumor ablation shown to reduce tumor burden effectively, particularly in deep-seated locations less amenable to gross total resection. We describe our initial technical experience of using the combination of LITT followed by surgical resection in patients with GBMs that exhibit both an easily accessible and deep-seated component. Materials and Methods Patients with GBM who received concurrent LITT and surgical resection at our institution were identified. Patient demographic and clinical information was procured from the University of Texas MD Anderson Cancer Center electronic medical record along with preoperative, postoperative, and 1-month follow-up magnetic resonance imaging (MRI). Results Four patients (n = 2 male, n = 2 female) with IDH-wild type GBM who received combined LITT and surgical resection were identified and analyzed retrospectively. All patients received chemoradiotherapy before presentation. All but one patient (75%) received resection before presentation. Median age was 54 years (range: 44–56 years). Median length of hospital stay was 6.5 days (range: 2–47 days). Median extent of combined ablation/resection was 90.4%. One of the four patients experienced complications in the perioperative or immediate follow-up periods. Local recurrence was observed in one patient during the follow-up period. Conclusion Malignant gliomas in deep-seated locations or in close proximity to white matter structures are challenging to manage. LITT followed by surgical resection may provide an alternative for tumor debulking that minimizes potential morbidities and extent of residual tumor. Further studies comparing this approach with standard resection techniques are warranted.

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

1992 ◽  
Vol 10 (4) ◽  
pp. 569-573 ◽  
Author(s):  
S D Fosså ◽  
H Qvist ◽  
A E Stenwig ◽  
H H Lien ◽  
S Ous ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Tumor Markers ◽  
Primary Tumor ◽  
Residual Disease ◽  
Mature Teratoma ◽  
Residual Tumor ◽  
Retroperitoneal Lymph Node Dissection ◽  
Retroperitoneal Mass ◽  
Residual Masses ◽  
Minimal Residual

PURPOSE At least one third of the patients with metastatic testicular cancer are rendered tumor-free by cisplatin-based chemotherapy. One may question, therefore, the routine use of postchemotherapy retroperitoneal lymph node dissection (RLND), especially if the residual masses are less than 20 mm in diameter. To define the role of such surgery, we analyzed the postchemotherapy histology in testicular cancer patients with minimal residual disease. PATIENTS AND METHODS Seventy-eight patients with advanced nonseminomatous testicular cancer underwent RLND after three to four cycles of cisplatin- or carboplatin-based chemotherapy. In all patients, the largest diameter of the residual retroperitoneal mass was less than 20 mm. RESULTS Complete fibrosis/necrosis was found in 51 patients, mature teratoma in 22, and vital malignant germ cell tumor in five. In two of the latter five patients, alphafetoprotein (AFP) had increased immediately before RLND. In the 76 patients with normal pre-RLND tumor markers, the presence of undifferentiated malignant teratoma (MTU) in the primary tumor and normal prechemotherapy tumor markers were independent parameters predicting complete fibrosis/necrosis, which was demonstrated in all 15 patients with these two pretreatment parameters. CONCLUSIONS Postchemotherapy RLND can be omitted in patients with MTU in the primary tumor who have normal AFP/human chorionic gonadotropin (AFP/HCG) before chemotherapy and whose residual retroperitoneal mass is less than 20 mm in diameter. If the pre-RLND tumor markers are normal, RLND should be performed in all other patients with small residual masses, even in the presence of a normal computed tomography (CT) and particularly if regular follow-up of the patients is not guaranteed.

Clinical characteristics and outcomes of patients with primary mediastinal germ cell tumors.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 389-389
Author(s):  
Siwat Sakdejayont ◽  
Chirawadee Sathitruangsak ◽  
Patrapim Sunpaweravong ◽  
Arunee Dechaphunkul
Keyword(s):  
Thoracic Surgery ◽  
Germ Cell ◽  
Surgical Resection ◽  
Clinical Characteristics ◽  
Germ Cell Tumors ◽  
Residual Tumor ◽  
Pulmonary Complications ◽  
Serological Response ◽  
Viable Tumor ◽  
Mediastinal Germ Cell Tumors

389 Background: Mediastinal germ cell tumors (MGCTs) account for 20% of all mediastinal tumors. Cisplatin-based chemotherapy followed by surgical resection of residual tumor remains the standard of care. To prevent pulmonary complications secondary to extensive thoracic surgery, non-bleomycin containing regimen is generally preferred. This study aims to review clinical characteristics and outcomes of these patients. Methods: A retrospective chart review was undertaken in patients with MGCTs treated in our institution between 1993 and 2013. Results: A total of 40 patients were enrolled with a median age of 24. Only one patient is female. Stratified by histology; eight patients (20%) had pure seminoma, 25 patients (62.5%) had pure non-seminoma, four patients (10%) had mixed seminoma and non-seminoma, and three patients (7.5%) had malignant transformation (two adenocarcinoma, one sarcoma). Median tumor size was 13 centimeters. Ninety-two percent of patients received chemotherapy as a first treatment modality, whereas 8% underwent upfront surgery. All patients received cisplatin-based chemotherapy: Eighty seven percent bleomycin, etoposide and cisplatin; 13% etoposide and cisplatin. Seventy-two percent of patients completed four planned cycles of chemotherapy. Thirty-one patients were able to assess radiological response: 3.2% complete response, 58.1% partial response, 29.0% stable disease, and 9.7% progressive disease. Forty-four percent of patients achieved completely serological response with chemotherapy. Seventeen patients underwent surgical resection of residual tumor. Among these, viable tumor was seen in 35% (6 out of 17 patients). No patients complicated with clinically significant pulmonary complications after thoracic surgery. The five year overall survival (OS) of patients with seminoma was 72.9% as compared with 19.9% in those with non-seminoma (p=0.012). For those who received chemotherapy followed by surgical resection with no viable tumor or only mature teratoma detected (N=11), the five year OS was 64.9%. Conclusions: Our study confirmed the importance of multi-modality approaches with primary chemotherapy followed by surgical resection of residual tumor. Bleomycin-containing regimen can be safely used in this setting.

Predictive factors for the histologicnature of residual tumor mass after chemotherapy in patients with advanced testicular cancer

Urology ◽  
1994 ◽  
Vol 44 (3) ◽  
pp. 392-398 ◽  
Author(s):  
Hideyasu Matsuyama ◽  
Shigeru Hayashida ◽  
Norio Yamamoto ◽  
Yoriaki Kamiryo ◽  
Jisaburou Sakatoku ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Predictive Factors ◽  
Residual Tumor ◽  
Tumor Mass ◽  
Advanced Testicular Cancer ◽  
Residual Tumor Mass
Sign in / Sign up

Export Citation Format

Share Document